SIGA TECHNOLOGIES, INC.

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING TO CLIN0001 FOR PEDIATRIC FORMULATION DEVELOPMENT, UPDATE ARTICLE B.2 BASE PERIOD, ARTICLE G.2. CONTRACTING OFFICER?S REPRESENTATIVE, AND SECTION J - LIST OF ATTACHMENTS, ATTACHMENT

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING TO CLIN0001 FOR THE TECHNICAL TRANSFER OF INTRAVENOUS TECOVIRIMAT TO A NEW CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO), UPDATE SECTION B - SUPPLIES OR SERVICES AND PRI

THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION CLIN 0023, 0025, AND 0027 AND UPDATE ARTICLE I.1 FEDERAL ACQUISITION REGULATIONS (FAR) (48 CFR CHAPTER 1) CLAUSES IN ACCORDANCE WITH CLASS DEVIATION (CD) NO. 2025-01 FROM THE FEDER

PROCUREMENT OF 23,030 TPOXX ORAL COURSES AND 50 TPOXX IV COURSES. TO MAINTAIN NATIONAL STOCKPILE.

THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION CLIN 0012 AND REVISE SECTION G CONTRACT ADMINISTRATION, ARTICLE G.1 CONTRACTING OFFICER FROM JONATHAN GONZALEZ TO AUDREY GLOVER.

TO DELIVER COURSES OF TPOXX TO REPLENISH THE NATIONAL STOCKPILE OF SMALLPOX TREATMENTS.

DEOBLIGATE CANCELLING FUNDS

EXERCISE OPTION CLIN 0011, 0018, 0020, 0022

TPOXX COURSE (OPTION)

TPOXX COURSE (BASE)

MOD TO CORRECT ERROR ON MOD 21

PROCURE UP TO 23000 TPOXX COURSES FOR SMALL POX TREATMENT.

DEOBLIGATION MOD

EXERCISE OPTIONAL CLINS 0002 AND 0004 TO PROCURE ADDITIONAL DOSES (10,885) OF TPOXX (SMALLPOX ANTIVIRAL THERAPEUTIC AND SHIPPING.

PROCURE COURSES OF FDA APPROVED TPOXX DRUG/THERAPEUTIC